Peptides for Depression: Selank, Semax, BPC-157, and Serotonergic Research

Depression is one of the most prevalent mental health conditions worldwide, affecting hundreds of millions of people. While conventional antidepressants work for many, a meaningful percentage of patients experience inadequate relief or intolerable side effects. Researchers have increasingly turned their attention to peptides — short chains of amino acids — as potential tools for supporting mood regulation through multiple biological pathways.

This post examines the evidence for several peptides that have attracted attention in depression research: Selank, Semax, BPC-157, and DSIP.

How Peptides May Influence Mood and Depression

Depression involves dysregulation across several interconnected systems: serotonin, dopamine, norepinephrine, GABA, glutamate, and the HPA (hypothalamic-pituitary-adrenal) axis. Neuroinflammation and impaired neuroplasticity also play central roles in treatment-resistant presentations.

Peptides can interact with many of these systems simultaneously, which is part of what makes them scientifically interesting. Unlike selective serotonin reuptake inhibitors (SSRIs), which act primarily on serotonin transporters, several peptides appear to modulate multiple neurotransmitter systems and promote BDNF (brain-derived neurotrophic factor) — a key driver of neuroplasticity and resilience.

Selank: Anxiolytic Peptide with Antidepressant Potential

Selank is a synthetic analog of the endogenous peptide tuftsin, developed by the Institute of Molecular Genetics in Russia. It has undergone clinical study in Russia and Ukraine for anxiety and depression.

Mechanism of action: Selank modulates the expression of genes involved in serotonin transport and metabolism. Research shows it increases BDNF levels in the hippocampus, a region implicated in both depression and antidepressant response. It also demonstrates effects on enkephalin metabolism, which may contribute to mood stabilization.

Research status: Phase II and III clinical trials in Russia have demonstrated Selank's anxiolytic effects at doses of 400–900 mcg intranasally. One 2008 study in Eksperimental'naia i Klinicheskaia Farmakologiia found Selank produced comparable anxiolytic effects to standard benzodiazepines without sedation or dependence risk. Its antidepressant-adjacent effects appear secondary to anxiolysis, making it most relevant for anxiety-depression comorbidity.

Administration: Typically 400–900 mcg intranasal, once or twice daily. See our intranasal peptides guide for administration details.

Semax: Cognitive and Mood Modulation

Semax is a synthetic heptapeptide derived from the N-terminal fragment of ACTH. It was developed in Russia and has a long history of clinical use there for cognitive and neurological conditions.

Mechanism of action: Semax powerfully upregulates BDNF and NGF (nerve growth factor) in the brain. It also modulates dopaminergic and serotonergic neurotransmission and has been shown to reduce expression of inflammatory cytokines in the CNS. This combination — neurotrophic support plus anti-neuroinflammatory activity — aligns with the leading neuroinflammatory hypothesis of depression.

Research findings: Studies in rodent models of depression show Semax produces antidepressant-like effects in forced swim tests and tail suspension tests. Human research, while largely confined to Russian publications, documents mood improvement alongside cognitive enhancement in patients with cerebrovascular disease. At 200–600 mcg intranasally per day, Semax appears well tolerated.

For a deeper dive into Semax's cognitive applications, see our Semax nootropic peptide guide.

BPC-157: Gut-Brain Axis and Serotonin

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from gastric juice proteins. While primarily known for tissue healing, accumulating research points to significant effects on mood and the gut-brain axis.

Serotonergic effects: Approximately 90% of the body's serotonin is produced in the gut. BPC-157 promotes gut mucosal healing, reduces intestinal permeability, and modulates the enteric nervous system — all of which may influence central serotonin signaling. Animal studies demonstrate that BPC-157 reverses depressive behavior induced by dopamine depletion, and interacts with both dopaminergic and serotonergic systems directly.

HPA axis modulation: BPC-157 appears to normalize dysregulated cortisol responses. Chronic stress and HPA axis hyperactivity are central to many cases of depression, and BPC-157's protective effects on the HPA axis may be one avenue through which it supports mood.

Neuroinflammation: BPC-157 inhibits NF-κB signaling and reduces pro-inflammatory cytokine production — effects that are relevant given the robust evidence linking neuroinflammation to depression.

Our full guide to BPC-157 covers dosing, protocols, and systemic applications.

DSIP: Sleep, Stress, and Mood

Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide first isolated in 1974 from rabbit cerebral venous blood during slow-wave sleep. Its relevance to depression lies in the well-established relationship between sleep dysregulation and mood disorders.

Mechanisms relevant to depression: DSIP modulates the stress response through interactions with the HPA axis, reducing corticotropin-releasing hormone (CRH) secretion. It has antioxidant properties and has been shown to reduce plasma cortisol levels in stress states. Given that sleep disruption precedes and exacerbates depressive episodes in many patients, DSIP's sleep-promoting and stress-buffering effects are potentially relevant.

Research limitations: DSIP research is sparse by modern standards, and most human data comes from older European studies. More rigorous clinical trials are needed. Our DSIP peptide guide reviews the available evidence in detail.

Neuroplasticity as a Unifying Framework

A key insight from modern depression research is that effective treatments tend to promote neuroplasticity — the brain's ability to reorganize and form new connections. Ketamine's rapid antidepressant effects, for example, are understood partly through BDNF upregulation and synaptogenesis.

Selank, Semax, and BPC-157 all demonstrate BDNF-promoting properties in preclinical research. This positions them alongside other neuroplasticity-supporting interventions like exercise, psychedelic-assisted therapy, and ketamine — though direct comparison studies in humans are lacking.

Safety and Research Limitations

None of these peptides are approved by the FDA for depression treatment in the United States. The majority of clinical research comes from Russia and Eastern Europe, with significant variability in study quality. Key limitations include:

• Small sample sizes in most human studies
• Limited long-term safety data
• Absence of large randomized controlled trials meeting Western regulatory standards
• Potential batch-to-batch variability in research-grade peptides

Anyone considering these peptides should do so under medical supervision and with realistic expectations about the current evidence base. See our overview of peptides as research chemicals for context on the regulatory landscape.

Practical Considerations for Researchers

Those exploring this area often combine peptides with conventional treatment rather than as replacements. Selank and Semax are commonly administered intranasally, which offers rapid CNS delivery. BPC-157 can be taken orally, intranasally, or subcutaneously depending on the target effect. DSIP is typically administered subcutaneously or intravenously.

A beginner-friendly overview of how to approach peptide protocols can be found in our peptides beginner guide.

Frequently Asked Questions

Q: Can peptides replace antidepressants? No. Peptides like Selank and Semax are not approved antidepressants and should not replace prescribed medications without medical supervision. They may be explored as adjuncts in research contexts.

Q: Is Selank legal in the US? Selank is not FDA-approved and exists in a gray legal area as a research chemical. It cannot be sold for human use, but possession is generally not prohibited. See our research chemicals guide for details.

Q: How long does it take for these peptides to show mood effects? Selank users often report effects within days due to its anxiolytic mechanism. Semax's neurotrophic effects may take weeks to manifest. Individual response varies considerably.

Q: Does BPC-157 directly affect the brain? Yes. BPC-157 crosses the blood-brain barrier and has been shown to interact with dopaminergic and serotonergic pathways in the CNS, in addition to its gut-brain axis effects.

Q: Are there any peptides approved for depression? Bremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder, but not depression. Kisspeptin analogs are in clinical trials for mood-related conditions. No peptide is currently FDA-approved specifically for depression.